

## Environmental and Social Data Sheet

### Overview

Project Name: *NORGINE R&D FACILITY*  
Project Number: *20110333*  
Country: *United Kingdom & France*  
*The Financing of NORGINE's pharmaceutical research and development from 2012 to 2014.*

EIA required: no

Project included in Carbon Footprint Exercise<sup>1</sup>: no

### Summary of Environmental and Social Assessment, including key issues and overall conclusion and recommendation

The R&D activities encompassed within this project will not materially change current R&D practices and will be carried out within existing facilities. Thus, an Environmental Impact Assessment (EIA) according to the Directive 2011/92/EU is not required.

### Environmental and Social Assessment

#### Environmental Assessment

R&D facilities and practices are in compliance with national and EU relevant regulation and the promoter maintains adequate internal procedures and management practices. Environmental audits are performed regularly.

#### Social Assessment, where applicable

The clinical trials which are included in the project are performed under regulated and strictly controlled conditions, in existing specialised facilities which are regularly inspected by competent authorities - EMA in Europe and/or national equivalent bodies in the rest of the World (FDA, PMDA, SFDA, etc). The recruitment of patients is performed in accordance with the European directive (2001/20/EC) and/or equivalent international regulations in case of clinical trials performed outside Europe.

---

<sup>1</sup> Only projects that meet the scope of the Pilot Exercise, as defined in the EIB draft Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: above 100,000 tons CO<sub>2</sub>e/year absolute (gross) or 20,000 tons CO<sub>2</sub>e/year relative (net) – both increases and savings.